You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK):NATULAN取得藥品註冊許可證
格隆匯 05-19 21:44

格隆匯5月19日丨李氏大藥廠(00950.HK)公吿,於2022年4月19日,Natulan(鹽酸丙卡巴肼膠囊)已取得中國國家藥品監督管理局的藥品註冊許可證。Natulan獲認可用於結合化療醫治成人霍奇金淋巴瘤。

有關認可建基於在中國進行的開放標籤、隨機、對照、多中心臨牀研究的結果,當中會比較基線BEACOPP(包括博來黴素、依託泊苷、鹽酸阿黴素(阿黴素)、環磷醯胺、長春新礆(安可平)、甲基苄肼及潑尼松的聯合化療)及ABVD(包括鹽酸阿黴素(阿黴素)、博來黴素、長春礆及達卡巴嗪的聯合化療)治療方案對晚期霍奇金淋巴瘤患者的安全客觀緩解率。合共93名晚期霍奇金淋巴瘤患者已入組,而研究不僅與其主要最終目標匹配(即基線BEACOPP組別的客觀緩解率不遜於ABVD組別),且於完成四個週期治療後,基線BEACOPP組別(每個週期21日)患者的完全緩解率亦顯着提高至16.22%(6/37),而ABVD組別(每個週期28日)則為2.17%(1/46)。

集團於2018年5月與Leadiant Biosciences簽訂一項分銷協議,獲得Natulan於大中華區的獨家商品化權利。

據悉,Natulan(鹽酸丙卡巴肼膠囊)結合化療適用於醫治霍奇金淋巴瘤及若干腦癌(如多形性膠質母細胞瘤),為一組稱為烷化劑的藥物的其中一項。Hoffmann-La Roche為Natulan原開發公司,最先送交專利存檔並聲稱擁有Natulan的籌備過程及用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account